Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
BA Frederick, BA Helfrich, CD Coldren, D Zheng… - Molecular cancer …, 2007 - AACR
The modest response of patients with head and neck squamous cell carcinoma (HNSCC)
and non–small cell lung carcinoma (NSCLC) to epithelial growth factor receptor tyrosine
kinase inhibitors such as gefitinib and erlotinib indicates the need for the development of
biomarkers to predict response. We determined gefitinib sensitivity in a panel of HNSCC cell
lines by a 5-day 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay and
confirmed these responses with analysis of downstream signaling by immunoblotting and …
and non–small cell lung carcinoma (NSCLC) to epithelial growth factor receptor tyrosine
kinase inhibitors such as gefitinib and erlotinib indicates the need for the development of
biomarkers to predict response. We determined gefitinib sensitivity in a panel of HNSCC cell
lines by a 5-day 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay and
confirmed these responses with analysis of downstream signaling by immunoblotting and …
